文献速递白血病造血干细胞移植与细胞治疗

阿伐替尼桥接异基因造血干细胞移植治疗7例伴KIT突变复发/难治性RUNX1-RUNX1T1阳性急性髓系白血病的疗效分析

[Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

该回顾性研究纳入2019年6月至2023年6月在苏州大学附属第一医院接受阿伐替尼桥接异基因造血干细胞移植的7例伴RUNX1-RUNX1T1融合基因与KIT突变的复发/难治性急性髓系白血病患者,评估疗效。4例在阿伐替尼治疗后获完全缓解,6例KIT突变转阴;移植后全部植入且微小残留病转阴,5例融合基因转阴,2例死于移植后感染。作者认为该策略对伴KIT-D816突变患者可能有效、安全。

要点

  • 7例均伴KIT突变(D816V阳性5例,D816Y阳性2例),难治2例、复发5例。
  • 阿伐替尼治疗后4例达完全缓解,6例KIT突变转阴。
  • 移植后全部植入、微小残留病转阴,5例融合基因转阴,2例死于感染。

核心结论

  • 阿伐替尼桥接异基因造血干细胞移植对于伴有KIT-D816突变的RUNX1-RUNX1T1阳性急性髓系白血病患者可能是一种有效、安全的治疗新策略。

研究设计与样本

  • 回顾性研究,纳入2019年6月至2023年6月在苏州大学附属第一医院接受阿伐替尼桥接异基因造血干细胞移植治疗的7例伴RUNX1-RUNX1T1融合基因与KIT突变的复发/难治性急性髓系白血病患者。

主要发现

  • 7例患者中男1例、女6例,中位年龄37(18~56)岁。
  • 7例均伴KIT突变(D816V突变阳性5例,D816Y突变阳性2例),难治患者2例,复发患者5例(均为骨髓复发)。
  • 所有患者移植前至少完成1个疗程阿伐替尼治疗;4例在阿伐替尼治疗后获得完全缓解,6例KIT基因突变转阴,1例KIT基因突变负荷较前下降。
  • 全相合无关供者移植3例,单倍体移植4例,所有患者均接受改良Bu/Cy预处理方案。
  • 移植后所有患者均顺利植入,复查骨髓象均达完全缓解且微小残留病转阴,5例患者融合基因转阴,移植后2例患者死于感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy of avatinib plus allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia (AML) with KIT mutations. Method: A retrospective study was conducted on the clinical data of seven relapsed/refractory AML patients containing the RUNX1-RUNX1T1 fusion gene and KIT mutation who received afatinib plus allo-HSCT treatment at the First Affiliated Hospital of Soochow University from June 2019 to June 2023. Results: The seven AML patients included one male and six females with a median age of 37 (18-56) years. All seven patients had KIT mutations (five positive for D816V and two positive for D816Y) . There were two refractory patients and five relapsed patients (all of whom had bone marrow recurrence) . All patients had to complete at least one course of treatment with afatinib before transplantation. Four patients achieved complete remission (CR) after treatment with afatinib, six patients had negative KIT gene mutations, and one had a decreased KIT gene mutational burden. There were three cases of unrelated identical transplantation and four cases of haploidentical transplantation. All patients received the modified Bu/Cy pretreatment regimen. After transplantation, all patients were successfully implanted and a bone marrow examination showed CR and minimal residual disease turned negative. Five patients exhibited negative fusion genes. Two patients died from infection following transplantation. Conclusion: Afatinib plus allo-HSCT may be an effective and safe new treatment strategy for RUNX1-RUNX1T1 positive AML patients with KIT-D816 mutation. 目的: 探讨阿伐替尼桥接异基因造血干细胞移植(allo-HSCT)治疗伴KIT突变复发/难治性RUNX1-RUNX1T1阳性急性髓系白血病(AML)的疗效。 方法: 对2019年6月至2023年6月期间在苏州大学附属第一医院接受阿伐替尼桥接allo-HSCT治疗的7例伴RUNX1-RUNX1T1融合基因与KIT突变的复发/难治性AML患者进行回顾性研究。 结果: 7例AML患者中男1例,女6例,中位年龄37(18~56)岁。7例患者均伴有KIT突变(D816V突变阳性5例,D816Y突变阳性2例)。难治患者2例,复发患者5例(均为骨髓复发)。所有患者移植前至少完成1个疗程阿伐替尼治疗。4例患者在阿伐替尼治疗后获得完全缓解(CR),6例患者KIT基因突变转阴,1例患者KIT基因突变负荷较前下降。全相合无关供者移植3例,单倍体移植4例。所有患者均接受改良Bu/Cy预处理方案。移植后所有患者均顺利植入,复查骨髓象均达CR且微小残留病(MRD)转阴,5例患者融合基因转阴。移植后2例患者死于感染。 结论: 阿伐替尼桥接allo-HSCT对于伴有KIT-D816突变的RUNX1-RUNX1T1阳性AML患者可能是一种有效、安全的治疗新策略。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Han SY, Zhou HX, Han Y, et al. [Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39307724. doi:10.3760/cma.j.cn121090-20240526-00188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。